Impact of PSCA Polymorphisms on the Risk of Duodenal Ulcer.


Journal

Journal of epidemiology
ISSN: 1349-9092
Titre abrégé: J Epidemiol
Pays: Japan
ID NLM: 9607688

Informations de publication

Date de publication:
05 Jan 2021
Historique:
pubmed: 17 12 2019
medline: 6 5 2021
entrez: 17 12 2019
Statut: ppublish

Résumé

While duodenal ulcer (DU) and gastric cancer (GC) are both H. pylori infection-related diseases, individuals with DU are known to have lower risk for GC. Many epidemiological studies have identified the PSCA rs2294008 T-allele as a risk factor of GC, while others have found an association between the rs2294008 C-allele and risk of DU and gastric ulcer (GU). Following these initial reports, however, few studies have since validated these associations. Here, we aimed to validate the association between variations in PSCA and the risk of DU/GU and evaluate its interaction with environmental factors in a Japanese population. Six PSCA SNPs were genotyped in 584 DU cases, 925 GU cases, and 8,105 controls from the Japan Multi-Institutional Collaborative Cohort (J-MICC). Unconditional logistic regression models were applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between the SNPs and risk of DU/GU. PSCA rs2294008 C-allele was associated with per allele OR of 1.34 (95% CI, 1.18-1.51; P = 2.28 × 10 Our study confirms an association between the PSCA rs2294008 C-allele and the risk of DU in a Japanese population.

Sections du résumé

BACKGROUND BACKGROUND
While duodenal ulcer (DU) and gastric cancer (GC) are both H. pylori infection-related diseases, individuals with DU are known to have lower risk for GC. Many epidemiological studies have identified the PSCA rs2294008 T-allele as a risk factor of GC, while others have found an association between the rs2294008 C-allele and risk of DU and gastric ulcer (GU). Following these initial reports, however, few studies have since validated these associations. Here, we aimed to validate the association between variations in PSCA and the risk of DU/GU and evaluate its interaction with environmental factors in a Japanese population.
METHODS METHODS
Six PSCA SNPs were genotyped in 584 DU cases, 925 GU cases, and 8,105 controls from the Japan Multi-Institutional Collaborative Cohort (J-MICC). Unconditional logistic regression models were applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between the SNPs and risk of DU/GU.
RESULTS RESULTS
PSCA rs2294008 C-allele was associated with per allele OR of 1.34 (95% CI, 1.18-1.51; P = 2.28 × 10
CONCLUSIONS CONCLUSIONS
Our study confirms an association between the PSCA rs2294008 C-allele and the risk of DU in a Japanese population.

Identifiants

pubmed: 31839644
doi: 10.2188/jea.JE20190184
pmc: PMC7738644
doi:

Substances chimiques

Antigens, Neoplasm 0
DNA, Neoplasm 0
GPI-Linked Proteins 0
Genetic Markers 0
Immunoglobulin G 0
Neoplasm Proteins 0
PSCA protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-20

Références

Lancet. 2017 Aug 5;390(10094):613-624
pubmed: 28242110
Nat Genet. 2008 Jun;40(6):730-40
pubmed: 18488030
Biochem Biophys Res Commun. 2000 Sep 7;275(3):783-8
pubmed: 10973799
Gastroenterology. 1997 Dec;113(6):1983-91
pubmed: 9394739
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Nat Genet. 2012 Mar 04;44(4):430-4, S1-2
pubmed: 22387998
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2658-63
pubmed: 11226295
Gut. 2001 Sep;49(3):347-53
pubmed: 11511555
Cancer Res. 2001 Jun 15;61(12):4660-5
pubmed: 11406532
PLoS One. 2013 May 21;8(5):e63698
pubmed: 23704932
PLoS Genet. 2006 Dec;2(12):e190
pubmed: 17194218
Lancet. 2002 Jan 5;359(9300):14-22
pubmed: 11809181
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Int J Cancer. 2015 Sep 15;137(6):1362-73
pubmed: 25721731
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40
pubmed: 9465086
Ann Surg Oncol. 2006 Dec;13(12):1645-54
pubmed: 16957968
Nature. 2012 Nov 1;491(7422):56-65
pubmed: 23128226
Int J Cancer. 2009 Oct 15;125(8):1961-4
pubmed: 19582881
Expert Rev Gastroenterol Hepatol. 2015;9(12):1535-47
pubmed: 26470920
Carcinogenesis. 2019 Jul 4;40(5):661-668
pubmed: 30753327
Clin Microbiol Rev. 2006 Jul;19(3):449-90
pubmed: 16847081
Proc Biol Sci. 2011 Apr 22;278(1709):1183-8
pubmed: 20926441
Gastroenterology. 2011 Feb;140(2):435-41
pubmed: 21070776
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Int J Cancer. 2012 May 15;130(10):2417-27
pubmed: 21681742
Oncotarget. 2017 Sep 11;8(44):78011-78022
pubmed: 29100443
Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):317-23
pubmed: 17696755
Oncogene. 2000 Mar 2;19(10):1288-96
pubmed: 10713670
Nat Methods. 2013 Jan;10(1):5-6
pubmed: 23269371
Oncotarget. 2017 Dec 14;9(3):3936-3945
pubmed: 29423095
N Engl J Med. 1996 Jul 25;335(4):242-9
pubmed: 8657240

Auteurs

Yoshiaki Usui (Y)

Division of Cancer Information and Control, Department of Preventive Medicine, Aichi Cancer Center.
Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceuticals Sciences.

Keitaro Matsuo (K)

Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center.
Department of Epidemiology, Nagoya University Graduate School of Medicine.

Isao Oze (I)

Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center.

Tomotaka Ugai (T)

Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center.

Yuriko Koyanagi (Y)

Division of Cancer Information and Control, Department of Preventive Medicine, Aichi Cancer Center.

Yoshinobu Maeda (Y)

Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceuticals Sciences.

Hidemi Ito (H)

Division of Cancer Information and Control, Department of Preventive Medicine, Aichi Cancer Center.
Division of Descriptive Cancer Epidemiology, Nagoya University Graduate School of Medicine.

Asahi Hishida (A)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine.

Kenji Takeuchi (K)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine.

Takashi Tamura (T)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine.

Mineko Tsukamoto (M)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine.

Yuka Kadomatsu (Y)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine.

Megumi Hara (M)

Department of Preventive Medicine, Faculty of Medicine, Saga University.

Yuichiro Nishida (Y)

Department of Preventive Medicine, Faculty of Medicine, Saga University.

Ippei Shimoshikiryo (I)

Department of International Island and Community Medicine, Kagoshima University Graduate School of Medical and Dental Sciences.

Toshiro Takezaki (T)

Department of International Island and Community Medicine, Kagoshima University Graduate School of Medical and Dental Sciences.

Etsuko Ozaki (E)

Department of Epidemiology for Community Health and Medicine Kyoto Prefectural University of Medicine.

Daisuke Matsui (D)

Department of Epidemiology for Community Health and Medicine Kyoto Prefectural University of Medicine.

Isao Watanabe (I)

Department of Epidemiology for Community Health and Medicine Kyoto Prefectural University of Medicine.

Sadao Suzuki (S)

Department of Public Health, Nagoya City University Graduate School of Medical Sciences.

Miki Watanabe (M)

Department of Public Health, Nagoya City University Graduate School of Medical Sciences.

Hiroko Nakagawa-Senda (H)

Department of Public Health, Nagoya City University Graduate School of Medical Sciences.

Haruo Mikami (H)

Cancer Prevention Center, Chiba Cancer Center Research Institute.

Yohko Nakamura (Y)

Cancer Prevention Center, Chiba Cancer Center Research Institute.

Kokichi Arisawa (K)

Department of Preventive Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School.

Hirokazu Uemura (H)

Department of Preventive Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School.

Kiyonori Kuriki (K)

Laboratory of Public Health, University of Shizuoka.

Naoyuki Takashima (N)

Department of Public Health, Faculty of Medicine, Kindai University.

Aya Kadota (A)

Department of Public Health, Shiga University of Medical Science.

Hiroaki Ikezaki (H)

Department of General Internal Medicine, Kyushu University Hospital.

Masayuki Murata (M)

Department of General Internal Medicine, Kyushu University Hospital.

Masahiro Nakatochi (M)

Department of Nursing, Nagoya University Graduate School of Medicine.

Yukihide Momozawa (Y)

Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences.

Michiaki Kubo (M)

Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences.

Kenji Wakai (K)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH